ADVM - NASDAQ
Adverum Biotechnologies, Inc.
$4.36
+0.0000%Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
At a Glance
Live SnapshotAdverum Biotechnologies, Inc. Management Team
Dr. Setareh Seyedkazemi Pharm.D.
Chief Development Officer
Compensation
$705,621
Ms. Linda M. Rubinstein M.A.
Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer
Compensation
$713,240
Dr. Rabia Gurses Ozden M.D.
Chief Medical Officer
Compensation
$795,099
Mr. Kishor Peter Soparkar J.D.
Chief Operating Officer
Compensation
$725,617
Ms. Dena House
Chief People Officer
Dr. Romuald Corbau Ph.D.
Chief Scientific Officer
Dr. R. Andrew Ramelmeier Ph.D.
Chief Technology Officer
Ms. Aneta Ferguson
General Counsel
Dr. Laurent Fischer
President, Chief Executive Officer & Director
Compensation
$1,120,675
Ms. Carla Fiankan
Senior Vice President of Regulatory Affairs
Adverum Biotechnologies, Inc. Insider Positioning
During the last 12 months, insiders have purchased $966K and sold $18.21M worth of ADVM shares, resulting in $17.24M of net selling activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
117.6K
506.92K
0
0.00
+507K
+$507K
6-9 Months
61.1K
258.00K
1.1M
4.61M
-4.4M
-$4.35M
9-12 Months
86.7K
201.24K
199.5K
13.60M
-13.4M
-$13.40M
Top Buyers
Fischer Laurent
Director, Officer: Ceo, President And Director
$554K
Soparkar Peter
Officer: Chief Operating Officer
$211K
Hong Soo
Director
$24K
Nicholson, C. David
Director
$24K
Whitcup Scott M
Director
$24K
Top Sellers
Fischer Laurent
Director, Officer: Ceo, President And Director
$9.14M
Leonard Braden Michael
10 Percent Owner
$4.61M
Soparkar Peter
Officer: Chief Operating Officer
$2.75M
Seyedkazemi Setareh
Officer: Chief Development Officer
$906K
Rubinstein Linda M
Officer: Chief Financial Officer
$697K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $17.24M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Insider Participation
5 insider buyers and 5 sellers. Equal participation suggests mixed or neutral insider views.
SEC Filings
ADVM - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | April 28, 2025 | June 17, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | May 02, 2024 | June 17, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 25, 2023 | June 09, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 26, 2022 | June 10, 2022 | 2022 | |
DEF 14A DEF 14A 2020 N/A | April 28, 2020 | June 23, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | June 17, 2019 | July 31, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 20, 2018 | May 31, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | April 26, 2017 | June 08, 2017 | 2017 | |
DEF 14A DEF 14A 2015 N/A | April 30, 2015 | June 26, 2015 | 2015 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.